Preclinical models of pancreatic ductal adenocarcinoma

Journal of Pathology

Volumn 238, Issue 2, 2016, Pages 197-204

  Hwang, Chang Il ^a,b   Boj, Sylvia F ^c,d   Clevers, Hans ^c   Tuveson, David A ^a,e  

^a Simons Center for Quantitative Biology   (United States)

^b Lustgarten Foundation Pancreatic Cancer Laboratory at Cold Spring Harbor   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Foundation Hubrecht Organoid Technology (HUB)   (Netherlands)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

organoid; pancreatic cancer; patient derived tumour xenograft; preclinical model

Indexed keywords

CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; CANCER SURVIVAL; CAUSE OF DEATH; CELL POPULATION; CELL PROLIFERATION; DRUG RESPONSE; GENE DOSAGE; HUMAN; IN VITRO STUDY; PANCREAS ADENOCARCINOMA; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CARCINOMA, PANCREATIC DUCTAL; CELL CULTURE TECHNIQUE; DISEASE MODEL; MOUSE; PANCREATIC NEOPLASMS; PRECLINICAL STUDY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84951279536     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4651     Document Type: Review

References (79)

1. Siegel RL, Miller KD, Jemal A,. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
2. Rahib L, Smith BD, Aizenberg R, et al., Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014; 74: 2913-2921.
3. Kanda M, Matthaei H, Wu J, et al., Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 2012; 142: 730-733 e739.
4. Morris JP IV, Wang SC, Hebrok M,. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 2010; 10: 683-695.
5. Hruban RH, Adsay NV, Albores-Saavedra J, et al., Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001; 25: 579-586.
6. Hingorani SR, Wang L, Multani AS, et al., Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7: 469-483.
7. Izeradjene K, Combs C, Best M, et al., Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 2007; 11: 229-243.
8. Bardeesy N, Aguirre AJ, Chu GC, et al., Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 2006; 103: 5947-5952.
9. Waddell N, Pajic M, Patch A-M, et al., Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015; 518: 495-501.
10. Biankin AV, Waddell N, Kassahn KS, et al., Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012; 491: 399-405.
11. Perez-Mancera PA, Rust AG, van der Weyden L, et al., The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 2012; 486: 266-270.
12. Mann KM, Ward JM, Yew CC, et al., Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci USA 2012; 109: 5934-5941.
13. Rad R, Rad L, Wang W, et al., A conditional piggyBac transposition system for genetic screening in mice identifies oncogenic networks in pancreatic cancer. Nat Genet 2015; 47: 47-56.
14. Scherer WF, Syverton JT, Gey GO,. Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med 1953; 97: 695-710.
15. Dobrynin YV,. Establishment and Characteristics of Cell Strains from Some Epithelial Tumors of Human Origin. J Natl Cancer Inst 1963; 31: 1173-1195.
16. Deer EL, González-Hernández J, Coursen JD, et al., Phenotype and genotype of pancreatic cancer cell lines. Pancreas 2010; 39: 425-435.
17. Henderson MC, Gonzales IM, Arora S, et al., High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells. Mol Cancer Res 2011; 9: 724-732.
18. Azorsa DO, Gonzales IM, Basu GD, et al., Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med 2009; 7: 43.
19. Yuan Y, Hartland K, Boskovic Z, et al., A small-molecule inducer of PDX1 expression identified by high-throughput screening. Chem Biol 2013; 20: 1513-1522.
20. Cheung HW, Cowley GS, Weir BA, et al., Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci USA 2011; 108: 12372-12377.
21. Collisson EA, Sadanandam A, Olson P, et al., Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011; 17: 500-503.
22. Jeon J, Nim S, Teyra J, et al., A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening. Genome Med 2014; 6: 57.
23. Rückert F, Aust D, Böhme I, et al., Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method. J Surg Res 2012; 172: 29-39.
24. Froeling FE, Marshall JF, Kocher HM,. Pancreatic cancer organotypic cultures. J Biotechnol 2010; 148: 16-23.
25. Masters JR,. Human cancer cell lines: fact and fantasy. Nat Rev Mol Cell Biol 2000; 1: 233-236.
26. Fidler IJ,. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3: 453-458.
27. Gadaleta E, Cutts RJ, Kelly GP, et al., A global insight into a cancer transcriptional space using pancreatic data: importance, findings and flaws. Nucleic Acids Res 2011; 39: 7900-7907.
28. Gillet JP, Varma S, Gottesman MM,. The clinical relevance of cancer cell lines. J Natl Cancer Inst 2013; 105: 452-458.
29. Clohessy JG, Pandolfi PP,. Mouse hospital and co-clinical trial project-from bench to bedside. Nat Rev Clin Oncol 2015; 12: 491-498.
30. Sharpless NE, DePinho RA,. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006; 5: 741-754.
31. Peterson JK, Houghton PJ,. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 2004; 40: 837-844.
32. Johnson JI, Decker S, Zaharevitz D, et al., Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001; 84: 1424-1431.
33. Voskoglou-Nomikos T, Pater JL, Seymour L,. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003; 9: 4227-4239.
34. End DW, Smets G, Todd AV, et al., Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001; 61: 131-137.
35. Van Cutsem E, van de Velde H, Karasek P, et al., Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-1438.
36. Bruns CJ, Harbison MT, Davis DW, et al., Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000; 6: 1936-1948.
37. Philip PA, Benedetti J, Corless CL, et al., Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010; 28: 3605-3610.
38. Tinari N, De Tursi M, Grassadonia A, et al., An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors. Curr Cancer Drug Targets 2012; 12: 439-452.
39. Donadelli M, Costanzo C, Beghelli S, et al., Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 2007; 1773: 1095-1106.
40. Richards DA, Boehm KA, Waterhouse DM, et al., Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann Oncol 2006; 17: 1096-1102.
41. Koutsounas I, Giaginis C, Theocharis S,. Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials? World J Gastroenterol 2013; 19: 1173-1181.
42. Mak IW, Evaniew N, Ghert M,. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res 2014; 6: 114-118.
43. Takimoto CH,. Why drugs fail: of mice and men revisited. Clin Cancer Res 2001; 7: 229-230.
44. Aparicio S, Hidalgo M, Kung AL,. Examining the utility of patient-derived xenograft mouse models. Nat Rev Cancer 2015; 15: 311-316.
45. Feig C, Gopinathan A, Neesse A, et al., The pancreas cancer microenvironment. Clin Cancer Res 2012; 18: 4266-4276.
46. Frese KK, Tuveson DA,. Maximizing mouse cancer models. Nat Rev Cancer 2007; 7: 645-658.
47. Tentler JJ, Tan AC, Weekes CD, et al., Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012; 9: 338-350.
48. Toolan HW,. Growth of human tumors in cortisone-treated laboratory animals: the possibility of obtaining permanently transplantable human tumors. Cancer Res 1953; 13: 389-394.
49. Garber K., From human to mouse and back: 'tumorgraft' models surge in popularity. J Natl Cancer Inst 2009; 101: 6-8.
50. Loukopoulos P, Kanetaka K, Takamura M, et al., Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas 2004; 29: 193-203.
51. Fu X, Guadagni F, Hoffman RM,. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci USA 1992; 89: 5645-5649.
52. Rubio-Viqueira B, Hidalgo M,. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther 2009; 85: 217-221.
53. Hidalgo M, Bruckheimer E, Rajeshkumar NV, et al., A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011; 10: 1311-1316.
54. Garrido-Laguna I, Uson M, Rajeshkumar NV, et al., Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res 2011; 17: 5793-5800.
55. Ryan DP, Hong TS, Bardeesy N,. Pancreatic adenocarcinoma. N Engl J Med 2014; 371: 2140-2141.
56. Rubio-Viqueira B, Jimeno A, Cusatis G, et al., An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006; 12: 4652-4661.
57. Yachida S, Jones S, Bozic I, et al., Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-1117.
58. Walters DM, Stokes JB, Adair SJ, et al., Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens. PloS One 2013; 8: e77065.
59. Boj SF, Hwang C-I, Baker LA, et al., Organoid models of human and mouse ductal pancreatic cancer. Cell 2015; 160: 324-338.
60. Boj SF, Hwang C-I, Baker LA, et al., Model Organoids Provide New Research Opportunities for Ductal Pancreatic Cancer. Mol Cell Oncol 2015; DOI: 10.1080/23723556.2015.1014757.
61. Rimann M, Graf-Hausner U,. Synthetic 3D multicellular systems for drug development. Curr Opin Biotechnol 2012; 23: 803-809.
62. Zschenker O, Streichert T, Hehlgans S, et al., Genome-wide gene expression analysis in cancer cells reveals 3D growth to affect ECM and processes associated with cell adhesion but not DNA repair. PloS One 2012; 7: e34279.
63. Ghosh S, Spagnoli GC, Martin I, et al., Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study. J Cell Physiol 2005; 204: 522-531.
64. Ridky TW, Chow JM, Wong DJ, et al., Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia. Nat Med 2010; 16: 1450-1455.
65. Debnath J, Brugge JS,. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005; 5: 675-688.
66. Petersen OW, Ronnov-Jessen L, Howlett AR, et al., Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci USA 1992; 89: 9064-9068.
67. Jung P, Sato T, Merlos-Suarez A, et al., Isolation and in vitro expansion of human colonic stem cells. Nat Med 2011; 17: 1225-1227.
68. +ve stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 2010; 6: 25-36.
69. + liver stem cells induced by Wnt-driven regeneration. Nature 2013; 494: 247-250.
70. Sato T, Vries RG, Snippert HJ, et al., Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009; 459: 262-265.
71. Sato T, Stange DE, Ferrante M, et al., Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 2011; 141: 1762-1772.
72. Huch M, Gehart H, van Boxtel R, et al., Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell 2015; 160: 299-312.
73. Huch M, Bonfanti P, Boj SF, et al., Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis. EMBO J 2013; 32: 2708-2721.
74. Gao D, Vela I, Sboner A, et al., Organoid cultures derived from patients with advanced prostate cancer. Cell 2014; 159: 176-187.
75. van de Wetering M, Francies HE, Francis JM, et al., Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 2015; 161: 933-945.
76. Olive KP, Jacobetz MA, Davidson CJ, et al., Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-1461.
77. Kim J, Hoffman JP, Alpaugh RK, et al., An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Cell Rep 2013; 3: 2088-2099.
78. Drost J, van Jaarsveld RH, Ponsioen B, et al., Sequential cancer mutations in cultured human intestinal stem cells. Nature 2015; 521: 43-47.
79. Matano M, Date S, Shimokawa M, et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med 2015; 21: 256-262.